

August 14, 2019

Q1FY20 Result Update

☑ Change in Estimates | ■ Target | ■ Reco

Change in Estimates

	Cu	rrent	Previous		
	FY20E	FY21E	FY20E	FY21E	
Rating	ACCU	MULATE	ACCUN	IULATE	
Target Price	1,	120	1,	120	
Sales (Rs. m)	14,667	16,930	14,667	16,930	
% Chng.	-	-			
EBITDA (Rs. m)	3,549	4,131	3,549	4,131	
% Chng.	-	-			
EPS (Rs.)	30.2	35.0	29.8	34.7	
% Chng.	1.2	0.7			

Key Financials - Consolidated

Y/e Mar	FY18	FY19	FY20E	FY21E
Sales (Rs. m)	10,570	12,034	14,667	16,930
EBITDA (Rs. m)	2,641	2,936	3,549	4,131
Margin (%)	25.0	24.4	24.2	24.4
PAT (Rs. m)	1,709	1,992	2,516	2,916
EPS (Rs.)	20.5	23.9	30.2	35.0
Gr. (%)	10.5	16.6	26.3	15.9
DPS (Rs.)	-	-	-	-
Yield (%)	-	-	-	-
RoE (%)	24.6	22.9	24.7	24.3
RoCE (%)	33.3	29.4	31.2	31.1
EV/Sales (x)	7.9	6.8	5.5	4.6
EV/EBITDA (x)	31.7	27.8	22.6	19.0
PE (x)	51.7	44.4	35.1	30.3
P/BV (x)	11.2	9.3	8.1	6.7

Key Data	DLPA.NS DLPL IN
52-W High / Low	Rs.1,180 / Rs.813
Sensex / Nifty	36,958 / 10,926
Market Cap	Rs.88bn/ \$ 1,241m
Shares Outstanding	83m
3M Avg. Daily Value	Rs.196.54m

Shareholding Pattern (%)

Promoter's	58.10
Foreign	19.30
Domestic Institution	9.23
Public & Others	13.37
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(1.4)	4.2	12.3
Relative	3.4	1.9	15.1

Surajit Pal

surajitpal@plindia.com | 91-22-66322259

Dr. Lal PathLabs (DLPL IN)

Rating: ACCUMULATE | CMP: Rs1,061 | TP: Rs1,120

Q1 in line; Favorable product mix leads margin

DLPL's revenue, adj. EBITDA and PAT grew 15%, 21% and 19% YoY respectively in Q1FY20 and in line with our estimates in margin and earnings. With strong cash flow and growth in new customers and packaged offer, the company expects to maintain current growth in FY20E. The expansion of bundle-test offer and gradual ramp up of central lab in Kolkata (KRL) to improve further volume addition in FY20E and FY21E. Management expects competitive intensity to remain strong with price war, regulatory interference and expected price ceiling of government. DLPL remain confident of its brand power, service quality, high-end test capability, network of collection centers and KRL to drive volume growth and profitability in FY19-21E. We maintain "Accumulate" and retain TP at Rs1,120.

Bundle offer, product mix, lower costs drive Margin: Revenue growth was aided by a) increase in volumes by 17% and b) product mix that drove higher contribution of bundle-test package. Its margin improved due to rationalisation on the number of clinical labs and re-routing many tests (at regional labs) to central lab in Delhi and Kolkata. Increase in patient volumes was driven by aggressive contribution from bundle-offer package and commencement of KRL. DLPL's overall realisations however declined marginally as moderate growth in high-end tests is offset by lower realizations of bundle-test business. KRL's operating performance having stabilized and DLPL now focus on to penetrate further in West Bengal. Management is highly optimistic on growth in volumes from KRL going forward

DLPL to continue growth in patient volumes; maintain guidance at 15% growth in FY20E: DLPL's revenue growth of 15% YoY in Q1FY20 was driven by patient volumes (aided mainly by budled-tests) of 17% and sample growth of 19.8%. DLPL's revenues/patient declined marginally to Rs684 in Q1FY20 vs. Rs691 in Q1FY19 due to price rationalisation undertaken in select geographies, which was partially offset by higher realisation from specialty tests, which contrinue to be its focus in high-end package of tests. Test per patient in Q1FY20 improved to 2.4 vs 2.3 from Q1FY19

Wellness and bundled packages contributes 15% revnues: Commencement of Wellness portfolio since Q2FY18 has seen good growth and DLPL remained optimistic in expansion of this volume-driven business through various channels like online and through its trade partners.


Future growth driven by franchisee model: Alongwith focus on rationalising prices in bulk tests, DLPL has also increased the channel margins as, 35% (earlier 30%) of revenues are contributed by the franchisees. With focus on expanding franchise business, DLPL guided that incremental growth of 50-60% would be contributed by franchisees going forward.

Exhibit 1: Q1FY20 Result Overview (Rs mn)

Y/e March	Q1FY20	Q1FY19	YoY gr. (%)	Q4FY19	FY20E	FY19	YoY gr. (%)
Net Sales	3,352	2,923	14.7	3,011	14,667	12,034	21.9
Raw Material	712	642	10.9	652	3,168	2,624	20.7
% of Net Sales	21.2	22.0		21.7	21.6	21.8	
Personnel Cost	583	494	18.0	568	2,713	2,083	30.3
% of Net Sales	17.4	16.9		18.9	18.5	17.3	
Others	1,106	1,037	6.7	1,129	5,236	4,391	19.2
% of Net Sales	33.0	35.5		37.5	35.7	36.5	
Total Expenditure	2,401	2,173	10.5	2,349	11,118	9,098	22.2
EBITDA	951	750	26.8	662	3,549	2,936	20.9
Margin (%)	28.4	25.7		22.0	24.2	24.4	
Depreciation	163	88	85.2	104	372	382	(2.7)
EBIT	788	662	19.0	558	3,178	2,554	24.4
Other Income	144	94	53.2	135	492	460	7.0
Interest	38	2		1	2	8	
PBT	894	754	18.6	692	3,668	3,006	22.0
Extra-Ord. Inc./Exps.	-	-		-	-	-	
Total Taxes	303	257	17.9	218	1,137	1,001	13.6
ETR (%)	33.9	34.1		31.5	31.0	33.3	
Reported PAT	591	497	18.9	474	2,531	2,005	26.2
Minority Interest	3	3		3	15	13	
Reported PAT	588	494	19.0	471	2,516	1,992	26.3

Source: Company, PL






Source: Company, PL












Exhibit 4: EBITDA increases 14.5% due to better product mix and high volume



Source: Company, PL


Exhibit 5: Reported EBITDA margin declines 60bps due to lower gross margin




Source: Company, PL














Source: Company, PL

Financials

Income Statement (Rs m)

income Statement (KS III)					Dalance Offeet Abstract (113)	,			
Y/e Mar	FY18	FY19	FY20E	FY21E	Y/e Mar	FY18	FY19	FY20E	FY21E
Net Revenues	10,570	12,034	14,667	16,930	Non-Current Assets				
YoY gr. (%)	15.8	13.9	21.9	15.4					
Cost of Goods Sold	2,260	2,624	3,168	3,657	Gross Block	2,307	2,269	2,919	3,569
Gross Profit	8,310	9,410	11,499	13,273	Tangibles	2,043	1,954	2,554	3,154
Margin (%)	78.6	78.2	78.4	78.4	Intangibles	265	315	365	415
Employee Cost	1,807	2,083	2,713	3,047					
Other Expenses	-	-	-	-	Acc: Dep / Amortization	511	710	1,081	1,478
					Tangibles	445	596	932	1,291
EBITDA	2,641	2,936	3,549	4,131	Intangibles	67	113	150	187
YoY gr. (%)	11.6	11.2	20.9	16.4					
Margin (%)	25.0	24.4	24.2	24.4	Net fixed assets	1,796	1,807	1,838	2,091
					Tangibles	1,598	1,601	1,622	1,863
Depreciation and Amortization	331	382	372	397	Intangibles	198	206	215	228
EBIT	2,310	2,554	3,178	3,734	Capital Work In Progress	96	34	34	34
Margin (%)	21.9	21.2	21.7	22.1	Goodwill	312	280	266	253
					Non-Current Investments	379	203	207	211
Net Interest	8	8	2	1	Net Deferred tax assets	169	215	178	136
Other Income	312	460	492	517	Other Non-Current Assets	206	230	253	278
Profit Before Tax	2,614	3,006	3,668	4,250	Current Assets				
Margin (%)	24.7	25.0	25.0	25.1	Investments	1,448	1,848	1,922	1,999
0 ()					Inventories	273	285	269	321
Total Tax	895	1,001	1,137	1,318	Trade receivables	412	532	683	835
Effective tax rate (%)	34.2	33.3	31.0	31.0	Cash & Bank Balance	3,135	4,903	6,348	8,032
					Other Current Assets	161	96	101	106
Profit after tax	1,719	2,005	2,531	2,933	Total Assets	9,189	10,905	12,594	14,864
Minority interest	10	13	15	17					
Share Profit from Associate	-	-	-	-	Equity				
					Equity Share Capital	833	833	833	833
Adjusted PAT	1,709	1,992	2,516	2,916	Other Equity	7,078	8,622	10,068	12,275
YoY gr. (%)	10.8	16.6	26.3	15.9	Total Networth	7,911	9,455	10,902	13,109
Margin (%)	16.2	16.6	17.2	17.2					
Extra Ord. Income / (Exp)	-	-	-	-	Non-Current Liabilities				
					Long Term borrowings	-	-	-	-
Reported PAT	1,709	1,992	2,516	2,916	Provisions	-	-	-	-
YoY gr. (%)	10.8	16.6	26.3	15.9	Other non current liabilities	4	-	-	-
Margin (%)	16.2	16.6	17.2	17.2					
					Current Liabilities				
Other Comprehensive Income	-	-	-	-	ST Debt / Current of LT Debt	-	-	-	-
Total Comprehensive Income	1,709	1,992	2,516	2,916	Trade payables	655	798	799	852
Equity Shares O/s (m)	83	83	83	83	Other current liabilities	505	585	626	607
EPS (Rs)	20.5	23.9	30.2	35.0	Total Equity & Liabilities	9,188	10,904	12,594	14,864

P

Cash Flow (Rs m)

Y/e Mar	FY18	FY19	FY20E	FY21E
РВТ	2,614	3,006	3,668	4,250
Add. Depreciation	331	382	372	397
Add. Interest	8	8	2	1
Less Financial Other Income	312	460	492	517
Add. Other	(137)	1,884	(3,712)	(782)
Op. profit before WC changes	2,816	5,280	330	3,865
Net Changes-WC	95	455	(136)	(264)
Direct tax	(940)	(1,001)	(1,137)	(1,318)
Net cash from Op. activities	1,971	4,733	(943)	2,283
Capital expenditures	(722)	(650)	(650)	(650)
Interest / Dividend Income	271	391	418	439
Others	(1,272)	(400)	(74)	(77)
Net Cash from Invt. activities	(1,723)	(659)	(306)	(288)
Issue of share cap. / premium	445	-	-	-
Debt changes	-	-	-	-
Dividend paid	(318)	(484)	(611)	(708)
Interest paid	(1)	(8)	(2)	(1)
Others	-	-	-	-
Net cash from Fin. activities	125	(492)	(614)	(709)
Net change in cash	373	3,582	(1,863)	1,287
Free Cash Flow	1,249	4,083	(1,593)	1,633
Source: Company Data, PL Resea	rch			

Y/e Mar	FY18	FY19	FY20E	FY21E
Per Share(Rs)				
EPS	20.5	23.9	30.2	35.0
CEPS	24.5	28.5	34.6	39.7
BVPS	94.9	113.5	130.8	157.3
FCF	15.0	49.0	(19.1)	19.6
DPS	-	-	-	-
Return Ratio(%)				
RoCE	33.3	29.4	31.2	31.1
ROIC	64.6	88.2	114.9	130.5
RoE	24.6	22.9	24.7	24.3
Balance Sheet				
Net Debt : Equity (x)	(0.6)	(0.7)	(0.8)	(0.8)
Net Working Capital (Days)	1	1	4	7
Valuation(x)				
PER	51.7	44.4	35.1	30.3
P/B	11.2	9.3	8.1	6.7
P/CEPS	43.3	37.2	30.6	26.7
EV/EBITDA	31.7	27.8	22.6	19.0
EV/Sales	7.9	6.8	5.5	4.6
Dividend Yield (%)	-	-	-	-

Quarterly Financials (Rs m)

Y/e Mar	Q2FY19	Q3FY19	Q4FY19	Q1FY20
Net Revenue	3,175	2,925	3,011	3,352
YoY gr. (%)	14.2	11.3	12.9	14.7
Raw Material Expenses	677	653	652	712
Gross Profit	2,498	2,272	2,359	2,640
Margin (%)	78.7	77.7	78.3	78.8
EBITDA	868	656	662	951
YoY gr. (%)	11.4	15.9	3.4	26.8
Margin (%)	27.3	22.4	22.0	28.4
Depreciation / Depletion	94	96	104	163
EBIT	774	560	558	788
Margin (%)	24.4	19.1	18.5	23.5
Net Interest	2	3	1	38
Other Income	109	122	135	144
Profit before Tax	881	679	692	894
Margin (%)	27.7	23.2	23.0	26.7
Total Tax	307	218	218	303
Effective tax rate (%)	34.8	32.1	31.5	33.9
Profit after Tax	574	461	474	591
Minority interest	4	3	3	3
Share Profit from Associates	-	-	-	-
Adjusted PAT	570	458	471	588
YoY gr. (%)	12.6	27.2	17.5	19.0
Margin (%)	18.0	15.7	15.6	17.5
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	570	458	471	588
YoY gr. (%)	12.6	27.2	17.5	19.0
Margin (%)	18.0	15.7	15.6	17.5
Other Comprehensive Income	1	1	(23)	-
Total Comprehensive Income	571	459	448	588
Avg. Shares O/s (m)	83	83	83	83
EPS (Rs)	6.8	5.5	5.7	7.1

Key Operating Metrics

Y/e Mar	FY18	FY19	FY20E	FY21E

Source: Company Data, PL Research

Source. Company Data, FL Resea

Dr. Lal PathLabs

Dr. Lal PathLabs

Price Chart



No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	4-Jul-19	Accumulate	1,120	1,077
2	20-May-19	Accumulate	1,120	1,072
3	5-Apr-19	Accumulate	1,070	1,034
4	11-Feb-19	Accumulate	1,070	1,031
5	7-Jan-19	Accumulate	1,009	948
6	7-Nov-18	Accumulate	1,009	885
7	5-Oct-18	Accumulate	1,009	928

Recommendation History

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aurobindo Pharma	BUY	715	600
2	Cadila Healthcare	Accumulate	266	232
3	Cipla	Reduce	439	518
4	Dr. Lal PathLabs	Accumulate	1,120	1,077
5	Dr. Reddy's Laboratories	Accumulate	2,997	2,648
6	Eris Lifesciences	Accumulate	459	402
7	Glenmark Pharmaceuticals	Reduce	417	423
8	Indoco Remedies	Hold	137	160
9	Ipca Laboratories	BUY	908	949
10	Jubilant Life Sciences	Reduce	433	445
11	Lupin	Reduce	730	761
12	Sun Pharmaceutical Industries	Reduce	396	392
13	Thyrocare Technologies	BUY	595	466

PL's Recommendation Nomenclature (Absolute Performance)

Buy	:	> 15%
Accumulate	:	5% to 15%
Hold	:	+5% to -5%
Reduce	:	-5% to -15%
Sell	:	< -15%
Not Rated (NR)	:	No specific call on the stock
Under Review (UR)	:	Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/l, Mr. Surajit Pal- PGDBA, CFA, M.Com Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Surajit Pal- PGDBA, CFA, M.Com Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all o the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com | Bloomberg Research Page: PRLD <GO>